EUVIMEDEUVIMED entdecken
Crossref

Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis

Hagop Kantarjian, Rami Komrokji, Jason Gotlib, Elliott Winton, Ruben Mesa

The Journal of Community and Supportive Oncology · 2013

DOI: 10.12788/j.cmonc.0054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Hagop Kantarjian und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kantarjian, H., Komrokji, R., Gotlib, J., Winton, E., & Mesa, R. (2013). Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0054

Vancouver

Kantarjian H, Komrokji R, Gotlib J, Winton E, Mesa R. Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0054

BibTeX
@article{Kantarjian2013,
  author = {Kantarjian, Hagop and Komrokji, Rami and Gotlib, Jason and Winton, Elliott and Mesa, Ruben},
  title = {Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis},
  journal = {The Journal of Community and Supportive Oncology},
  year = {2013},
  doi = {10.12788/j.cmonc.0054}
}
Kostenlos starten →